paroxysmal nocturnal hemoglobinuria (PNH) | Page 5 | Aplastic Anemia & MDS International Foundation

paroxysmal nocturnal hemoglobinuria (PNH)

Rodrigo Calado, MD, PhD

Calado, Rodrigo
Associate Professor
Hospital das Clínicas de Ribeirão Preto

Graduated in Medicine (1997) and PhD in Clinical Medicine (2003) from the Ribeirão Preto Medical School of the University of São Paulo (FMRP-USP) and medical residency in Hematology and Hemotherapy (2001) from the Hospital das Clinicas of FMRP-USP. He did postdoctoral studies at the National Institutes of Health, Bethesda, Maryland, USA, where he also worked as a Staff Scientist at the Hematology Branch until 2011.

Marlise Luskin, MD, MSCE

Luskin, Marlise
Physician
Dana Farber Cancer Institute

Dr. Luskin received her MD from the University of Pennsylvania Perelman School of Medicine in 2009. She completed residency training in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Hematology and Oncology at the University of Pennsylvania. She joined Dana-Farber as a member of the Adult Leukemia program in 2016.

Melhem Solh, MD

Solh, Melhem
Northside Hospital Blood and Marrow Transplant and Leukemia Program physician
Northside Hospital Cancer Institute

Melhem Solh, M.D., is board certified in the subspecialties of medical oncology and hematology. Dr. Solh is a Northside Hospital Blood and Marrow Transplant and Leukemia Program physician.In 2019, Dr. Solh was recognized as among Atlanta’s Top Doctors in his specialty by Castle Connolly.

rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study (CONSERVE)

Patients with diseases requiring complement inhibition who have previously taken part in Akari clinical trials and who wish to continue to receive rVA576 (Coversin) after their active participation in the previous trial has completed and patients treated under compassionate use or named patient arrangements who wish to continue on rVA576 (Coversin) therapy.